DGAP-News: co.don AG

DGAP-News: co.don Aktiengesellschaft: 'Focus Spezial' includes co.don AG in its list of Growth Champions for 2016

DGAP-News: co.don Aktiengesellschaft / Key word(s): Miscellaneous co.don Aktiengesellschaft: 'Focus Spezial' includes co.don AG in its list of Growth Champions for 2016

03.12.2015 / 10:04 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Press release

"Focus Spezial" includes co.don AG in its list of Growth Champions for 2016

- 7th place in the category Chemicals and Pharma

Teltow, 03 December 2015 - The news magazine "Focus" has included co.don AG in its list of Growth Champions for 2016, which is published in the Focus Spezial issue.

Growth Champions 2016 presents the list of the 500 fastest growing companies in Germany, classified by industry and defined by their average revenue growth. co.don AG came in 7th place in the Chemicals and Pharma sector.

Dirk Hessel, CEO of co.don AG, commented, "I am delighted by this recognition. Our sales success in recent years is closely connected with the growing success of our main product co.don chondrosphere(R), a minimally invasive cell therapy for cartilage defects. Being included as a Growth Champion acknowledges the performance of the whole co.don team over recent years, but it also motivates us going forward, because we are aiming for EU marketing authorisation for co.don chondrosphere(R) by the end of 2017. That will open up the entire European market for our products: so our greatest growth potential still lies ahead."

About co.don AG: The minimally invasive cell therapy company

Berlin-based co.don AG develops, produces and markets in Germany autologous cell therapies for the minimally invasive repair of cartilage damage to joints following traumatic or degenerative defects. co.don chondrosphere(R) is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). co.don chondrosphere(R) has been approved by the German federal agency PEI in accordance with Section 4b of the German Pharmaceuticals Act (AMG) and is currently undergoing Phase II and III clinical trials to obtain European marketing authorisation. co.don chondrosphere(R) has been used for more than 10 years in over 120 clinics to treat more than 8,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007 and for the treatment of vertebral joints since 2008. The shares in co.don AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227).

Executive Board: Dirk Hessel (CEO) and Vilma Methner (COO, CSO)

Further information is available from www.codon.de

Press contact

Matthias Meißner, M.A.

Corporate Communications / IR / PR

pr@codon.de

Tel: +49 (0)3328 43460

Fax: +49 (0)3328 434643



---------------------------------------------------------------------------

03.12.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English Company: co.don Aktiengesellschaft Warthestraße 21 14513 Teltow Germany Phone: 03328 43460 Fax: 03328 434643 E-mail: info@codon.de Internet: www.codon.de ISIN: DE000A1K0227 WKN: A1K022 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange End of News DGAP News Service ---------------------------------------------------------------------------

420811 03.12.2015